Liu Guiyuan, Chen Dehu, Zhao Xiaojun, You Xiaolan, Huang Chuanjiang, Cheng Zhiyi, Mao Xunan, Zhou Haihua
Department of General Surgery, Taizhou People's Hospital, Taizhou, China.
J Oncol. 2022 Jul 12;2022:5473292. doi: 10.1155/2022/5473292. eCollection 2022.
The aim of the study is to explore the efficacy and safety of dendritic cell-cytokine-induced killer cell (DC-CIK) immunotherapy combined with chemotherapy in the treatment of locally advanced gastric cancer (LAGC). Among 106 patients with LAGC, 53 received the treatment of oxaliplatin-5-fluorouracil chemotherapy (control group), while the remaining 53 received DC-CIK immunotherapy combined with chemotherapy (DC-CIK group). The short-term efficacy and the changes in immune function indexes (cluster of differentiation (CD)3, CD4, CD8, CD4/CD8, and natural killer (NK) cells) were analyzed. The overall response rate (ORR) was 47.2% (25/53) and 41.5% (22/53), and the disease control rate (DCR) was 69.8% (37/53) and 50.9% (27/53), respectively, in the DC-CIK group and the control group. It could be seen that the ORR had no statistically significant difference between the two groups, while the DCR in the DC-CIK group was significantly better than that in the control group. After treatment, the proportions of CD3 T lymphocytes, CD4 T lymphocytes, CD4/CD8 cells, and NK cells obviously rose, while the proportion of CD8 T lymphocytes obviously declined in the DC-CIK group compared with those in the control group. After treatment, the scores in the function module of the QLQ-C30 scale were greatly higher in the DC-CIK group than those in the control group, while the scores of loss of appetite, constipation, dyspnea, fatigue, pain, and sleep disorders in the symptom module were significantly lower in the DC-CIK group than those in the control group. The median survival time was 23.4 months and 18.6 months, respectively, in the DC-CIK group and the control group. The results of the log-rank test showed that the OS in the DC-CIK group was remarkably superior to that in the control group. DC-CIK immunotherapy combined with chemotherapy can improve the immune cell function, ameliorate the quality of life, and prolong the survival time of LAGC patients, with fewer adverse reactions.
本研究旨在探讨树突状细胞因子诱导的杀伤细胞（DC-CIK）免疫疗法联合化疗治疗局部晚期胃癌（LAGC）的疗效和安全性。106例LAGC患者中，53例接受奥沙利铂-5-氟尿嘧啶化疗（对照组），其余53例接受DC-CIK免疫疗法联合化疗（DC-CIK组）。分析了短期疗效及免疫功能指标（分化簇（CD）3、CD4、CD8、CD4/CD8和自然杀伤（NK）细胞）的变化。DC-CIK组和对照组的总缓解率（ORR）分别为47.2%（25/53）和41.5%（22/53），疾病控制率（DCR）分别为69.8%（37/53）和50.9%（27/53）。可见，两组间ORR无统计学显著差异，而DC-CIK组的DCR明显优于对照组。治疗后，与对照组相比，DC-CIK组CD3 T淋巴细胞、CD4 T淋巴细胞、CD4/CD8细胞和NK细胞的比例明显升高，而CD8 T淋巴细胞的比例明显下降。治疗后，DC-CIK组QLQ-C30量表功能模块得分显著高于对照组，而症状模块中食欲减退、便秘、呼吸困难、疲劳、疼痛和睡眠障碍的得分显著低于对照组。DC-CIK组和对照组的中位生存时间分别为23.4个月和18.6个月。对数秩检验结果显示，DC-CIK组的总生存期明显优于对照组。DC-CIK免疫疗法联合化疗可改善LAGC患者的免疫细胞功能，提高生活质量，延长生存时间，且不良反应较少。
